Cargando…
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome
BACKGROUND: Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce weight and IR...
Autores principales: | Ma, Rui-Lin, Deng, Yan, Wang, Yan-Fang, Zhu, Shi-Yang, Ding, Xue-Song, Sun, Ai-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667970/ https://www.ncbi.nlm.nih.gov/pubmed/34732660 http://dx.doi.org/10.1097/CM9.0000000000001712 |
Ejemplares similares
-
Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
por: Hu, Yan, et al.
Publicado: (2023) -
The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020) -
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019) -
The Effect of Short-term Treatment with Metformin on Insulin Resistance among Obese Iraqi Women with Polycystic Ovary Syndrome
por: Findakly, Sura Basil, et al.
Publicado: (2021) -
The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials
por: Ye, Zheng-Rong, et al.
Publicado: (2023)